Imugene
Australia - SydneyBiotechnology
Focus: Imugene is an Australian-based biotech company focused on peptide immunotherapy and oncolytic virus platforms for oncology indications. The company is in early-stage clinical development with a diversified pipeline across multiple cancer types.
Profile data last refreshed Yesterday · AI intelligence enriched 2w ago
Open Jobs
0
About Imugene
AI assessmentNot HiringNo open roles listed right now. Follow Imugene to get notified when they start hiring — the background below is worth knowing for when they do.
Why Work Here
Data completeness
1/9 — Limited
Company HealthSolid
Pipeline
Early-stage
8 total
LOE Risk
Protected
No near-term cliffs
Hiring
0 open
Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.
Pipeline & Clinical Trials
Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cel
Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product (PBCAR) in a Precision BioSciences, Inc., Clinical StudyClinical Trials (1)
NCT05822427Long-term Follow-up of Study Participants Who Received an Allogeneic Chimeric Antigen Receptor T-Cell Product in an Imugene Ltd. Clinical Study
Help build intelligence for Imugene
No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.